mRNA-1083

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Care Career buys MAS Medical Staffing to expand healthcare workforce platform

China uses water cannon against Philippine vessels for second day near Scarborough Shoal

Energy Action reports A$12.2m FY2026 revenue as higher costs pressure earnings

IBM’s planned acquisition of HRL Laboratories could strengthen its quantum computing roadmap by adding silicon-spin qubit technology and expanding its advanced semiconductor research capabilities. Representative image.

Inside the quantum foundry race behind IBM’s move for HRL Laboratories

Representative image of Moderna’s mRNA-1083 combo COVID–flu vaccine candidate, now expected to be resubmitted for FDA review by late 2025, with a 2026 commercial launch on the horizon.

What happened to Moderna’s combo COVID–flu–RSV vaccine—and is it still in the race for 2026?

Moderna’s combo COVID–flu vaccine has been delayed to 2026 after FDA feedback. Find out what caused the setback and whether the mRNA-1083 shot can still launch next year.

μFR system
αvβ6-integrin
α4β7 integrin
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures

September 3, 2025